382 related articles for article (PubMed ID: 18369536)
1. The pharmacodynamic properties of azithromycin in a kinetics-of-kill model and implications for bacterial conjunctivitis treatment.
Dorfman MS; Wagner RS; Jamison T; Bell B; Stroman DW
Adv Ther; 2008 Mar; 25(3):208-17. PubMed ID: 18369536
[TBL] [Abstract][Full Text] [Related]
2. Long-term, low-dose azithromycin treatment reduces the incidence but increases macrolide resistance in Staphylococcus aureus in Danish CF patients.
Hansen CR; Pressler T; Hoiby N; Johansen HK
J Cyst Fibros; 2009 Jan; 8(1):58-62. PubMed ID: 18849202
[TBL] [Abstract][Full Text] [Related]
3. Pharmacodynamic activity of azithromycin against macrolide-susceptible and -resistant Streptococcus pneumoniae simulating clinically achievable free serum, epithelial lining fluid and middle ear fluid concentrations.
Zhanel GG; DeCorby M; Noreddin A; Mendoza C; Cumming A; Nichol K; Wierzbowski A; Hoban DJ
J Antimicrob Chemother; 2003 Jul; 52(1):83-8. PubMed ID: 12775677
[TBL] [Abstract][Full Text] [Related]
4. Microbiologic effect of bovine cerebrospinal fluid and azithromycin against Neisseria meningitidis, Streptococcus pneumoniae, and Haemophilus influenzae.
Destache CJ; Pakiz CB; Kersting K
Pharmacotherapy; 1997; 17(5):985-9. PubMed ID: 9324186
[TBL] [Abstract][Full Text] [Related]
5. Comparison of fluoroquinolone kinetics of kill in susceptible and resistant gram-positive conjunctival pathogens.
D'Arienzo PA; Wagner RS; Jamison T; Bell B; Dajcs JJ; Stroman DW
Adv Ther; 2010 Jan; 27(1):39-47. PubMed ID: 20174904
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic/pharmacodynamic modeling of in vitro activity of azithromycin against four different bacterial strains.
Treyaprasert W; Schmidt S; Rand KH; Suvanakoot U; Derendorf H
Int J Antimicrob Agents; 2007 Mar; 29(3):263-70. PubMed ID: 17194570
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of 50S ribosomal subunit assembly in Haemophilus influenzae cells by azithromycin and erythromycin.
Champney WS; Miller M
Curr Microbiol; 2002 Jun; 44(6):418-24. PubMed ID: 12000992
[TBL] [Abstract][Full Text] [Related]
8. Ocular TRUST: nationwide antimicrobial susceptibility patterns in ocular isolates.
Asbell PA; Colby KA; Deng S; McDonnell P; Meisler DM; Raizman MB; Sheppard JD; Sahm DF
Am J Ophthalmol; 2008 Jun; 145(6):951-958. PubMed ID: 18374299
[TBL] [Abstract][Full Text] [Related]
9. A time-kill evaluation of clarithromycin and azithromycin against two extracellular pathogens and the development of resistance.
Burgess DS; Hastings RW; Horan JL
Ann Pharmacother; 1999 Dec; 33(12):1262-5. PubMed ID: 10630825
[TBL] [Abstract][Full Text] [Related]
10. Speed of bacterial kill with a fluoroquinolone compared with nonfluoroquinolones: clinical implications and a review of kinetics of kill studies.
Lichtenstein SJ; Wagner RS; Jamison T; Bell B; Stroman DW
Adv Ther; 2007; 24(5):1098-111. PubMed ID: 18029337
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and antibacterial activity of novel 11,12-cyclic carbonate azithromycin 4''-O-carbamate derivatives.
Ma C; Liu Z; Song H; Jiang R; He F; Ma S
J Antibiot (Tokyo); 2010 Jan; 63(1):3-8. PubMed ID: 19911029
[TBL] [Abstract][Full Text] [Related]
12. In vitro activity of the ketolide ABT-773.
Barry AL; Fuchs PC; Brown SD
Antimicrob Agents Chemother; 2001 Oct; 45(10):2922-4. PubMed ID: 11557491
[TBL] [Abstract][Full Text] [Related]
13. Azithromycin iv pharmacodynamic parameters predicting Streptococcus pneumoniae killing in epithelial lining fluid versus serum: an in vitro pharmacodynamic simulation.
Sevillano D; Alou L; Aguilar L; Echevarría O; Giménez MJ; Prieto J
J Antimicrob Chemother; 2006 Jun; 57(6):1128-33. PubMed ID: 16617063
[TBL] [Abstract][Full Text] [Related]
14. Antibiotic resistance among bacterial conjunctival pathogens collected in the Antibiotic Resistance Monitoring in Ocular Microorganisms (ARMOR) surveillance study.
Asbell PA; DeCory HH
PLoS One; 2018; 13(10):e0205814. PubMed ID: 30335799
[TBL] [Abstract][Full Text] [Related]
15. Microbiological features of acute bacterial conjunctivitis in a central Italian area.
Montagnani F; Malandrini A; Stolzuoli L; Lomurno L; Buccoliero D; Zanchi A
New Microbiol; 2008 Apr; 31(2):291-4. PubMed ID: 18623997
[TBL] [Abstract][Full Text] [Related]
16. Topical ophthalmic moxifloxacin elicits minimal or no selection of fluoroquinolone resistance among bacteria isolated from the skin, nose, and throat.
Lichtenstein SJ; De Leon L; Heller W; Marshall B; Cupp G; Foster K; McLean C; Levy S; Stroman DW
J Pediatr Ophthalmol Strabismus; 2012; 49(2):88-97. PubMed ID: 22074357
[TBL] [Abstract][Full Text] [Related]
17. Macrolide resistance of Staphylococcus aureus and Haemophilus species associated with long-term azithromycin use in cystic fibrosis.
Phaff SJ; Tiddens HA; Verbrugh HA; Ott A
J Antimicrob Chemother; 2006 Apr; 57(4):741-6. PubMed ID: 16469851
[TBL] [Abstract][Full Text] [Related]
18. Antimicrobial activity of the new macrolide flurithromycin against Haemophilus influenzae, Streptococcus pneumoniae, Streptococcus pyogenes, Branhamella catarrhalis and Staphylococcus aureus.
Nord CE; Lindmark A; Persson I
J Chemother; 1989 Jul; 1(4 Suppl):203-4. PubMed ID: 16312369
[No Abstract] [Full Text] [Related]
19. A pharmacodynamic approach to antimicrobial activity in serum and epithelial lining fluid against in vivo-selected Streptococcus pneumoniae mutants and association with clinical failure in pneumonia.
Alou L; Giménez MJ; Sevillano D; Aguilar L; Cafini F; Echeverría O; Pérez-Trallero E; Prieto J
J Antimicrob Chemother; 2006 Aug; 58(2):349-58. PubMed ID: 16782744
[TBL] [Abstract][Full Text] [Related]
20. Comparison of azithromycin and moxifloxacin against bacterial isolates causing conjunctivitis.
Ohnsman C; Ritterband D; O'Brien T; Girgis D; Kabat A
Curr Med Res Opin; 2007 Sep; 23(9):2241-9. PubMed ID: 17688706
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
